Olema Pharmaceuticals, Inc. 10-Q

Item 5. Other Information. Trading Plans or Rule 10b5-1 Trading Plans During the quarter ended March 31, 2026, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below. Name Position Action Date of Adoption/ Termination Type of Trading Arrangement Expiration Date Total Shares of Common Stock to be Sold*** Rule 10b5-1* Non-Rule 10b5-1** Sean Bohen, M.D., Ph.D. President and Chief Executive Officer Adoption March 3, 2026 X June 8, 2027 Up to 705,000 * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. ** "Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. *** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 trading arrangement . The number of shares to be sold was dependent on the satisfaction of certain conditions as set forth in the written plan. 113 Table of Contents Item 6. Exhibits. Incorporated by Reference Exhibit Number Description Schedule Form File Number Exhibit Filing Date 3.1 Amended and Restated Certificate of Incorporation. 8‑K 001‑39712 3.1 11/23/2020 3.2 Amended and Restated Bylaws. 8‑K 001‑39712 3.1 12/16/2022 10.1¥ Third Amendment to Loan and Security Agreement by and between the Registrant and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, dated January 11, 2026. 10-K 001‑39712 10.29 3/16/2026 10.2 Separation and Consulting Agreement by and between the Company and Shane Kovacs. 8-K 001‑39712 10.1 1/30/2026 10.3* Olema Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy. 10.4*¥ Lease Agreement, dated April 27, 2026, between KR Oyster Point II, LLC and Olema Pharmaceuticals, Inc. 31.1* Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rules 13a‑14(a) and 15d‑14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1*† Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document 101.SCH Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents 104 Cover page formatted as Inline XBRL and contained in Exhibit 101 * Filed herewith. † The certifications attached as Exhibit 32.1 accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Exchange Act, and are not to be incorporated 114 Table of Contents by reference into any of the Registrant’s filings under the Securities Act, irrespective of any general incorporation language contained in any such filing. ¥ Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit have been omitted as the Registrant has determined that the omitted information is the type that the Registrant customarily and actually treats as private or confidential and is not material. 115 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Olema Pharmaceuticals, Inc. Date: May 12, 2026 By: /s/ Sean Bohen, M.D., Ph.D. Sean Bohen, M.D., Ph.D. President and Chief Executive Officer ( Principal Executive Officer and Principal Financial Officer ) 116